Evidence map›Paper›PMID 33204811›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2020

Alzheimer-related altered white matter microstructural integrity in Down syndrome: A model for sporadic AD?

H Diana Rosas, Eugene Hsu, Nathaniel D Mercaldo, Florence Lai, Margaret Pulsifer, David Keator, Adam M Brickman, Julie Price, Michael Yassa, Christy Hom and 4 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Development of Molecular Neuropathology in Down Syndrome across the Lifespan.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Review
  5. Article
  6. Article
  7. Longitudinal diffusion tensor imaging correlates with amyloid burden in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome.International review of research in developmental disabilities · 2022
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

H Diana RosasDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Eugene HsuDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Nathaniel D MercaldoDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Florence LaiDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Margaret PulsiferDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
David KeatorDepartment of Psychiatry and Human Behavior University of California Irvine California USA.
Adam M BrickmanG. H. Sergievsky Center and Taub Institute for Research on Alzheimer's Disease and the Aging Brain College of Physicians and Surgeons Columbia University New York New York USA.
Julie PriceDepartment of Radiology Athinoula Martinos Center Massachusetts General Hospital Harvard Medical School Charlestown Massachusetts USA.
Michael YassaDepartment of Neurobiology and Behavior University of California California, USA Irvine.
Christy HomDepartment of Psychiatry and Human Behavior University of California Irvine California USA.
Sharon J Krinsky-McHaleNew York Institute for Basic Research in Developmental Disabilities New York New York USA.
Wayne SilvermanKennedy Krieger Institute Johns Hopkins University School of Medicine, Baltimore Maryland USA.
Ira LottDepartment of Pediatrics Irvine Medical Center University of California Irvine California USA.
Nicole SchupfG. H. Sergievsky Center and Taub Institute for Research on Alzheimer's Disease and the Aging Brain College of Physicians and Surgeons Columbia University New York New York USA.
Massachusetts General Hospital · USUniversity of California, Irvine · USColumbia University · USHarvard University · USUniversity of California, Irvine Medical Center · USNew York State Office for People With Developmental Disabilities · US

Funding

Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTIAN, BRADLEY T, HANDEN, BENJAMIN L · 2020 to 2025
$103.7M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Andrew Franklin Teich · 2020 to 2026
$30.1M
Biomarkers of Alzheimer's Disease in Adults with Down SyndromeU01AG051412 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LOTT, IRA T., SCHUPF, NICOLE · 2015 to 2019
$26.3M
NIA NIH HHS P30 AG066462NIA NIH HHS U01 AG051412NIA NIH HHS U19 AG068054
6 · The paper itself

Abstract

introductionVirtually all adults with Down syndrome (DS) develop Alzheimer's disease (AD)-associated neuropathology by the age of 40, with risk for dementia increasing from the early 50s. White matter (WM) pathology has been reported in sporadic AD, including early demyelination, microglial activation, loss of oligodendrocytes and reactive astrocytes but has not been extensively studied in the at-risk DS population.

methodsFifty-six adults with DS (35 cognitively stable adults, 11 with mild cognitive impairment, 10 with dementia) underwent diffusion-weighted magnetic resonance imaging (MRI), amyloid imaging, and had assessments of cognition and functional abilities using tasks appropriate for persons with intellectual disability.

resultsEarly changes in late-myelinating and relative sparing of early-myelinating pathways, consistent with the retrogenesis model proposed for sporadic AD, were associated with AD-related cognitive deficits and with regional amyloid deposition. DISCUSSION: Our findings suggest that quantification of WM changes in DS could provide a promising and clinically relevant biomarker for AD clinical onset and progression.

Indexed as

Alzheimer's diseaseDown syndromewhite matter integrity

Identifiers

PMID33204811
PMCPMC7648416
OpenAlexW3096710674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.